<!DOCTYPE html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1.0"><title>Complications Overview — SugarWise</title><link rel="stylesheet" href="styles.css">
    <link rel="icon" type="image/svg+xml" href="favicon.svg"><link rel="manifest" href="manifest.json"><meta name="theme-color" content="#1a7a5a"><meta property="og:type" content="website"><meta property="og:site_name" content="SugarWise"><meta property="og:url" content="https://aravindcleaerr.github.io/diabetes-guide/complications-overview.html"><meta property="og:description" content="Free educational diabetes management guide. Not medical advice."><meta property="og:image" content="https://aravindcleaerr.github.io/diabetes-guide/og-image.svg"></head><body>
    <a href="#main" class="skip-link">Skip to content</a>
<nav class="navbar"><div class="navbar-inner"><a class="brand" href="index.html">SugarWise</a><a class="lang-switch" href="complications-overview-kn.html">ಕನ್ನಡ</a><a class="home-link" href="index.html">All Topics</a></div></nav>
<div class="container" id="main" role="main">
<div class="page-header"><h1>Diabetes Complications Overview</h1><p>Understanding microvascular and macrovascular complications, the role of chronic hyperglycemia, and the importance of early screening and glycemic control.</p></div>
<div class="last-reviewed">Content last reviewed: January 2026 | AI-assisted content</div>

<div class="illus">
<svg width="160" height="180" viewBox="0 0 160 180" fill="none" xmlns="http://www.w3.org/2000/svg">
<ellipse cx="80" cy="172" rx="40" ry="5" fill="#e2e8f0"/>
<!-- head -->
<circle cx="80" cy="28" r="18" fill="#1a7a5a" opacity="0.85"/>
<!-- body -->
<rect x="60" y="48" width="40" height="55" rx="12" fill="#1a7a5a" opacity="0.75"/>
<!-- arms -->
<rect x="30" y="52" width="28" height="10" rx="5" fill="#1a7a5a" opacity="0.6"/>
<rect x="102" y="52" width="28" height="10" rx="5" fill="#1a7a5a" opacity="0.6"/>
<!-- legs -->
<rect x="62" y="105" width="14" height="55" rx="6" fill="#1a7a5a" opacity="0.65"/>
<rect x="84" y="105" width="14" height="55" rx="6" fill="#1a7a5a" opacity="0.65"/>
<!-- pulse indicators -->
<circle cx="80" cy="70" r="5" fill="#e53e3e" opacity="0.8"><animate attributeName="r" values="4;7;4" dur="1.5s" repeatCount="indefinite"/><animate attributeName="opacity" values="0.8;0.3;0.8" dur="1.5s" repeatCount="indefinite"/></circle>
<circle cx="80" cy="28" r="4" fill="#e8913a" opacity="0.7"><animate attributeName="r" values="3;6;3" dur="2s" repeatCount="indefinite"/><animate attributeName="opacity" values="0.7;0.3;0.7" dur="2s" repeatCount="indefinite"/></circle>
<circle cx="73" cy="130" r="3" fill="#e8913a" opacity="0.6"><animate attributeName="r" values="2;5;2" dur="1.8s" repeatCount="indefinite"/></circle>
</svg>
</div>

<div class="section">
<h2><span class="icon-sm">&#128161;</span> Why Complications Occur</h2>
<p>Chronic hyperglycemia damages blood vessels and nerves through several biochemical pathways, including the polyol pathway, advanced glycation end-products (AGEs), protein kinase C activation, and the hexosamine pathway. Over years, this damage accumulates and manifests as complications affecting nearly every organ system.</p>
<p>The risk of complications rises sharply with both the degree and duration of hyperglycemia. However, even modest improvements in glucose control significantly reduce long-term risk.</p>
</div>

<div class="section">
<h2><span class="icon-sm">&#128065;</span> Microvascular Complications</h2>
<p>Microvascular complications result from damage to small blood vessels (capillaries and arterioles). They are highly specific to diabetes.</p>
<h3>Retinopathy</h3>
<ul>
<li>Damage to the tiny blood vessels in the retina.</li>
<li>Leading cause of new blindness in adults aged 20-74.</li>
<li>Progresses from non-proliferative (microaneurysms, hemorrhages) to proliferative (new fragile vessel growth).</li>
<li>Macular edema can occur at any stage and is the most common cause of vision loss.</li>
</ul>
<h3>Nephropathy</h3>
<ul>
<li>Progressive kidney damage beginning with hyperfiltration and microalbuminuria.</li>
<li>Diabetes is the leading cause of end-stage renal disease (ESRD) worldwide.</li>
<li>Affects 20-40% of people with diabetes over their lifetime.</li>
<li>Early detection via urine albumin-to-creatinine ratio (UACR) allows intervention before irreversible damage.</li>
</ul>
<h3>Neuropathy</h3>
<ul>
<li>Affects up to 50% of people with diabetes.</li>
<li>Peripheral neuropathy causes numbness, tingling, and pain in the feet and hands.</li>
<li>Autonomic neuropathy affects the heart, digestive system, bladder, and sexual organs.</li>
<li>Major contributor to diabetic foot ulcers and amputations.</li>
</ul>
<div class="info-cards">
<div class="info-card"><span class="ic-icon">&#128065;</span><div class="ic-title">Microvascular</div><div class="ic-text">Small vessel damage: eyes, kidneys, nerves. Specific to diabetes.</div></div>
<div class="info-card"><span class="ic-icon">&#129729;</span><div class="ic-title">Macrovascular</div><div class="ic-text">Large vessel damage: heart, brain, legs. Accelerated by diabetes.</div></div>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#129729;</span> Macrovascular Complications</h2>
<p>Macrovascular complications involve damage to large blood vessels (arteries). They share risk factors with the general population but occur earlier, more frequently, and more severely in diabetes.</p>
<h3>Cardiovascular Disease (CVD)</h3>
<ul>
<li>The number one cause of death in people with diabetes.</li>
<li>Risk of heart attack is 2-4 times higher than in non-diabetic individuals.</li>
<li>Includes coronary artery disease, heart failure, and cardiomyopathy.</li>
<li>Diabetes is considered a "coronary heart disease equivalent" by many guidelines.</li>
</ul>
<h3>Stroke</h3>
<ul>
<li>Risk of ischemic stroke is 1.5-3 times higher.</li>
<li>Outcomes after stroke are worse in people with diabetes.</li>
<li>Hypertension control is critical for stroke prevention.</li>
</ul>
<h3>Peripheral Arterial Disease (PAD)</h3>
<ul>
<li>Reduced blood flow to the legs and feet due to atherosclerosis.</li>
<li>Symptoms include claudication (leg pain with walking), cold feet, and weak pulses.</li>
<li>Combined with neuropathy, PAD dramatically increases amputation risk.</li>
</ul>
</div>

<div class="section">
<h2><span class="icon-sm">&#127993;</span> The Role of Chronic Hyperglycemia</h2>
<p>Sustained high blood glucose is the central driver of diabetic complications. Key mechanisms include:</p>
<ul>
<li><strong>Oxidative stress:</strong> Excess glucose generates reactive oxygen species that damage endothelial cells.</li>
<li><strong>Inflammation:</strong> Hyperglycemia activates pro-inflammatory cytokines and adhesion molecules.</li>
<li><strong>Endothelial dysfunction:</strong> Impaired nitric oxide production reduces vasodilation and promotes clotting.</li>
<li><strong>Glycation:</strong> Glucose binds irreversibly to proteins (forming AGEs), altering their structure and function.</li>
</ul>
<div class="note">HbA1c reflects average blood glucose over 2-3 months and is the primary marker used to assess long-term glycemic control. Each 1% reduction in HbA1c is associated with significant reductions in complication risk.</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128218;</span> Landmark Clinical Trials</h2>
<h3>DCCT (Diabetes Control and Complications Trial) — Type 1</h3>
<ul>
<li>Intensive insulin therapy (HbA1c ~7%) vs. conventional therapy (~9%).</li>
<li>Intensive control reduced retinopathy risk by 76%, nephropathy by 50%, and neuropathy by 60%.</li>
<li>The follow-up EDIC study showed lasting benefits even after the trial ended ("metabolic memory").</li>
</ul>
<h3>UKPDS (United Kingdom Prospective Diabetes Study) — Type 2</h3>
<ul>
<li>Intensive glucose control (HbA1c ~7%) reduced microvascular complications by 25%.</li>
<li>Each 1% reduction in HbA1c was associated with a 37% reduction in microvascular endpoints and a 14% reduction in myocardial infarction.</li>
<li>Blood pressure control (<150/85) reduced stroke by 44% and diabetes-related deaths by 32%.</li>
<li>Long-term follow-up demonstrated a "legacy effect" — early intensive control provided lasting cardiovascular benefits.</li>
</ul>
<div class="tip">The message from both DCCT and UKPDS is clear: early, sustained glycemic control pays dividends for decades. Do not wait for complications to appear before optimizing glucose management.</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128197;</span> Recommended Screening Schedule</h2>
<div class="table-wrap">
<table>
<thead>
<tr><th>Complication</th><th>Screening Test</th><th>Frequency</th><th>When to Start</th></tr>
</thead>
<tbody>
<tr><td>Retinopathy</td><td>Dilated eye exam or retinal photography</td><td>Annually</td><td>Type 1: 5 years after diagnosis; Type 2: at diagnosis</td></tr>
<tr><td>Nephropathy</td><td>Urine albumin-to-creatinine ratio (UACR) + eGFR</td><td>Annually</td><td>Type 1: 5 years after diagnosis; Type 2: at diagnosis</td></tr>
<tr><td>Neuropathy</td><td>Comprehensive foot exam (monofilament, vibration, reflexes)</td><td>Annually</td><td>Type 1: 5 years after diagnosis; Type 2: at diagnosis</td></tr>
<tr><td>Cardiovascular disease</td><td>Blood pressure, lipid profile, ECG as indicated</td><td>Every visit / Annually</td><td>At diagnosis for all types</td></tr>
<tr><td>Peripheral arterial disease</td><td>Ankle-brachial index (ABI) if symptomatic; pulse exam</td><td>Annually</td><td>At diagnosis if risk factors present; age &gt;50</td></tr>
<tr><td>Dental</td><td>Comprehensive dental examination</td><td>Every 6 months</td><td>At diagnosis</td></tr>
<tr><td>Liver (NAFLD)</td><td>Liver function tests, ultrasound if elevated</td><td>Annually</td><td>At diagnosis for Type 2</td></tr>
</tbody>
</table>
</div>
</div>

<div class="section">
<h2><span class="icon-sm">&#128737;</span> Prevention: The Big Picture</h2>
<ul>
<li><strong>Glycemic control:</strong> Target HbA1c &lt;7% for most adults (individualized).</li>
<li><strong>Blood pressure:</strong> Target &lt;130/80 mmHg.</li>
<li><strong>Lipid management:</strong> Statin therapy for most adults with diabetes over age 40.</li>
<li><strong>Lifestyle:</strong> Regular physical activity, healthy diet, weight management, smoking cessation.</li>
<li><strong>Regular screening:</strong> Adhere to the schedule above — early detection changes outcomes.</li>
<li><strong>Medication adherence:</strong> Take prescribed medications consistently; discuss concerns with your care team.</li>
</ul>
<div class="warning">Complications can develop silently over years. Normal-feeling feet may have lost sensation. Clear vision does not mean the retina is healthy. Never skip screening appointments.</div>
</div>

<div class="page-nav">
<a class="prev" href="supplements.html">Supplements</a>
<a class="next" href="heart-health.html">Heart Health</a>
</div>
</div>
<div class="disclaimer">This content is for educational purposes only and does not replace professional medical advice. The creators of SugarWise are not medical professionals. Do not start, stop, or change any medication without consulting your doctor. In case of emergency, call 112 (India) or your local emergency number. <a href="terms-of-use.html">Read full Terms of Use &amp; Medical Disclaimer</a></div>
<div class="privacy-notice">SugarWise does not use cookies, collect personal data, or track users.</div>
<div class="footer"><span class="ai-badge">AI-Assisted Content</span><br>SugarWise &bull; Comprehensive Diabetes Management Companion &bull; <a href="terms-of-use.html">Terms of Use</a> &bull; Last updated: January 2026</div>
<button class="theme-toggle" id="themeToggle" aria-label="Toggle dark mode" title="Toggle dark mode">&#9790;</button>
<button class="scroll-top" aria-label="Scroll to top" id="scrollTop" title="Back to top">&uarr;</button>
<script>
var sb=document.getElementById('scrollTop');window.addEventListener('scroll',function(){sb.classList.toggle('visible',window.scrollY>400)});sb.addEventListener('click',function(){window.scrollTo({top:0,behavior:'smooth'})});
</script>
<script>
if('serviceWorker' in navigator){navigator.serviceWorker.register('sw.js');}
(function(){var t=document.getElementById('themeToggle');var saved=localStorage.getItem('theme');if(saved){document.documentElement.setAttribute('data-theme',saved);t.textContent=saved==='dark'?'\u2600':'\u263E';}t.addEventListener('click',function(){var d=document.documentElement.getAttribute('data-theme')==='dark'?'':'dark';document.documentElement.setAttribute('data-theme',d);localStorage.setItem('theme',d);t.textContent=d==='dark'?'\u2600':'\u263E';});})();
</script></body></html>